Compare KEN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | LQDA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | KEN | LQDA |
|---|---|---|
| Price | $79.32 | $38.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $38.60 |
| AVG Volume (30 Days) | 14.6K | ★ 1.7M |
| Earning Date | 04-01-2026 | 03-18-2026 |
| Dividend Yield | ★ 6.06% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | ★ $803,304,000.00 | $69,216,000.00 |
| Revenue This Year | N/A | $993.31 |
| Revenue Next Year | N/A | $219.14 |
| P/E Ratio | $8.54 | ★ N/A |
| Revenue Growth | 8.15 | ★ 343.41 |
| 52 Week Low | $27.10 | $11.26 |
| 52 Week High | $79.48 | $46.67 |
| Indicator | KEN | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 49.29 |
| Support Level | $71.30 | $38.88 |
| Resistance Level | $79.48 | $40.95 |
| Average True Range (ATR) | 1.69 | 2.30 |
| MACD | 0.27 | -0.76 |
| Stochastic Oscillator | 87.18 | 11.23 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.